EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Clinical outcomes of Day-7 blastocysts: a systematic review and meta-analysis

Julie Firmin, Bastien Ducreux, Haitam Saidessalam, Lucile Ferreux, Khaled Pocate-Cheriet, Ahmed Chargui, Chloé Maignien, Mathilde Bourdon, Pietro Santulli, Catherine Patrat, Patricia Fauque

Human Reproduction Update · 2026-11-01 · 32 (6) · 717-734

DOI: 10.1093/humupd/dmag017 ↗
AbstractBibliografische Angaben

Abstract

Abstract BACKGROUND Extended embryo culture beyond Day-6 remains controversial. While a small subset of embryos reaches the blastocyst stage on Day-7, their developmental competence and reproductive potential remain uncertain. Data from previous studies have been limited and heterogeneous, particularly for meta-analytical evaluation of euploid embryo transfers. OBJECTIVE AND RATIONALE This systematic review and meta-analysis compared clinical pregnancy (CPR) and live birth rates (LBR), as well as implantation (IR), miscarriage (MR), and ongoing pregnancy rates (OPR), between Day-7 frozen blastocysts and those obtained on Day-5 and/or Day-6. Euploidy rates by day of blastocyst development and available perinatal outcomes were also assessed. SEARCH METHODS Conducted according to PRISMA guidelines, this review included full-length English-language human studies, published up to 1 April 2026, comparing frozen transfers of Day-7 versus Day-5/6 blastocysts and reporting at least clinical pregnancy and/or live birth outcomes. Random-effects models were used to estimate pooled odds ratios (ORs) with 95% confidence intervals (95% CI). Obstetric and perinatal outcomes were analysed when available. OUTCOMES A total of 17 retrospective studies were included. Across 2908 Day-7 transfers, CPR and LBR were significantly lower than for Day-5 (CPR: OR 0.26, 95% CI 0.19–0.35, I2: 76.2%, 16 studies, 2799 and 34 442 transfers at Day-7 and Day-5, respectively; LBR: OR 0.23, 95% CI 0.16–0.33, I2: 76.3%, 12 studies, 2687 and 31 630 transfers at Day-7 and Day-5, respectively) and Day-6 blastocysts (CPR: OR 0.38, 95% CI 0.31–0.48, I2: 54.4%, 16 studies, 2799 and 28 563 transfers at Day-7 and Day-6, respectively; LBR: OR 0.37, 95% CI 0.28–0.49, I2: 60.2%, 12 studies, 2687 and 26 687 transfers at Day-7 and Day-6, respectively). Similarly, IR and OPR were significantly lower in the Day-7 group than in the Day-5 or Day-6 groups, while MR was higher compared with Day-5 blastocysts (OR 1.54, 95% CI 1.04–2.30, I2: 51.1%, 14 studies, 685 and 18 609 pregnancies at Day-7 and Day-5, respectively). When considering only PGT-A euploid blastocysts, CPR and LBR remained significantly lower in the Day-7 group compared with Day-5 (CPR: OR 0.21, 95% CI 0.14–0.33, I2: 58.0%, 7 studies, 365 and 7064 transfers at Day-7 and Day-5, respectively; LBR: OR 0.21, 95% CI 0.17–0.28, I2: 0%, 6 studies, 364 and 5924 transfers at Day-7 and Day-5, respectively) and Day-6 (CPR: OR 0.36, 95% CI 0.28–0.46, I2: 40.8%, 7 studies, 365 and 4617 transfers at Day-7 and Day-6, respectively; LBR: OR 0.36, 95% CI 0.28–0.46, I2: 0%, 6 studies, 364 and 3782 transfers at Day-7 and Day-6, respectively), and MR was higher than Day-5 (OR 2.78, 95% CI 1.57–4.89, I2: 32.4%, 6 studies, 95 and 4018 pregnancies at Day-7 and Day-5, respectively). Euploid rates were also significantly reduced for Day-7 blastocysts compared with Day-5 and Day-6. Data on perinatal outcomes were limited but overall reassuring. The pooled analyses revealed low to high heterogeneity across studies. WIDER IMPLICATIONS Despite lower success rates, including for euploid embryos, Day-7 blastocysts may still contribute to cumulative live birth rates, notably in poor-prognosis patients. Prospective studies are needed to better assess perinatal and long-term outcomes. REGISTRATION NUMBER PROSPERO (CRD420251114251)

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →